Cargando…

Integrated Clinical and Genomic Models to Predict Optimal Cytoreduction in High-Grade Serous Ovarian Cancer

SIMPLE SUMMARY: Approximately 30% of patients with advanced, high-grade serous ovarian cancer who undergo surgery will have a suboptimal result, resulting in decreased overall survival. Improving the ability to predict a successful surgery would improve survival. We aimed to use tumor genomics to cr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cardillo, Nicholas, Devor, Eric J., Pedra Nobre, Silvana, Newtson, Andreea, Leslie, Kimberly, Bender, David P., Smith, Brian J., Goodheart, Michael J., Gonzalez-Bosquet, Jesus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9323510/ https://www.ncbi.nlm.nih.gov/pubmed/35884615 http://dx.doi.org/10.3390/cancers14143554

Ejemplares similares

Investigating the effect of optimal cytoreduction in the context of platinum sensitivity in high‐grade serous ovarian cancer
por: Cardillo, Nicholas, et al.
Publicado: (2022)

Identification of Novel Fusion Transcripts in High Grade Serous Ovarian Cancer
por: Newtson, Andreea, et al.
Publicado: (2021)

Using Genomic Variation to Distinguish Ovarian High-Grade Serous Carcinoma from Benign Fallopian Tubes
por: Gonzalez-Bosquet, Jesus, et al.
Publicado: (2022)

Molecular Characterization of Non-responders to Chemotherapy in Serous Ovarian Cancer
por: McDonald, Megan E., et al.
Publicado: (2019)

Creation and validation of models to predict response to primary treatment in serous ovarian cancer
por: Gonzalez Bosquet, Jesus, et al.
Publicado: (2021)

Identification of Novel lncRNAs in Ovarian Cancer and Their Impact on Overall Survival
por: Cardillo, Nicholas, et al.
Publicado: (2021)

Prediction of chemo-response in serous ovarian cancer
por: Gonzalez Bosquet, Jesus, et al.
Publicado: (2016)

Differential DNA methylation in high-grade serous ovarian cancer (HGSOC) is associated with tumor behavior
por: Reyes, Henry D., et al.
Publicado: (2019)

p53 mutation status is a primary determinant of placenta-specific protein 1 expression in serous ovarian cancers
por: Devor, Eric J., et al.
Publicado: (2017)

Interval debulking surgery is not worth the wait: a National Cancer Database study comparing primary cytoreductive surgery versus neoadjuvant chemotherapy
por: Lyons, Yasmin A, et al.
Publicado: (2020)

Bacterial, Archaea, and Viral Transcripts (BAVT) Expression in Gynecological Cancers and Correlation with Regulatory Regions of the Genome
por: Gonzalez-Bosquet, Jesus, et al.
Publicado: (2021)

A nuclear polymorphism at the 8q24 region is associated with improved survival time and chemo-response in high-grade serous ovarian cancer
por: Ikoma, Danielle, et al.
Publicado: (2021)

Population Substructure Has Implications in Validating Next-Generation Cancer Genomics Studies with TCGA
por: Miller, Marina D., et al.
Publicado: (2019)

An integrated prediction model of recurrence in endometrial endometrioid cancers
por: Miller, Marina D, et al.
Publicado: (2019)

A Prediction Model for Preoperative Risk Assessment in Endometrial Cancer Utilizing Clinical and Molecular Variables
por: Salinas, Erin A., et al.
Publicado: (2019)

Disparity of ovarian cancer survival between urban and rural settings
por: Ulmer, Keely Krolikowski, et al.
Publicado: (2022)

Molecular and phenotypic characteristics influencing the degree of cytoreduction in high‐grade serous ovarian carcinomas
por: Torkildsen, Cecilie Fredvik, et al.
Publicado: (2023)

Microbial Communities in Gynecological Cancers and Their Association with Tumor Somatic Variation
por: Gonzalez-Bosquet, Jesus, et al.
Publicado: (2023)

Integration of Genomic and Clinical Retrospective Data to Predict Endometrioid Endometrial Cancer Recurrence
por: Gonzalez-Bosquet, Jesus, et al.
Publicado: (2022)

Impact of hemodynamic instability during cytoreductive surgery on survival in high-grade serous ovarian carcinoma
por: Kim, Se Ik, et al.
Publicado: (2022)

The Synthetic Curcumin Analog HO-3867 Rescues Suppression of PLAC1 Expression in Ovarian Cancer Cells
por: Devor, Eric J., et al.
Publicado: (2021)

TP53 oncomorphic mutations predict resistance to platinum- and taxane-based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma
por: BRACHOVA, PAVLA, et al.
Publicado: (2014)

The Uncertain Benefit of Adjuvant Chemotherapy in Advanced Low-Grade Serous Ovarian Cancer and the Pivotal Role of Surgical Cytoreduction
por: Johnson, Racheal Louise, et al.
Publicado: (2021)

Microscopic Peritoneal Residual Disease after Complete Macroscopic Cytoreductive Surgery for Advanced High Grade Serous Ovarian Cancer
por: Azaïs, Henri, et al.
Publicado: (2020)

Successful Patient-Derived Organoid Culture of Gynecologic Cancers for Disease Modeling and Drug Sensitivity Testing
por: Bi, Jianling, et al.
Publicado: (2021)

Low-grade Serous Ovarian Carcinoma
por: Ricciardi, Enzo, et al.
Publicado: (2018)

Traditional Systemic Treatment Options in Advanced Low-Grade Serous Ovarian Cancer after Successful Cytoreduction: A Systematic Review and Meta-Analysis
por: Montero-Macías, Rosa, et al.
Publicado: (2022)

Secondary surgical cytoreduction of thoracic metastasis in a high grade serous ovarian carcinoma by video-assisted thoracoscopic surgery (VATS) in 10 steps
por: Hermoza, Alejandro Delfos, et al.
Publicado: (2023)

Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma
por: Ducie, Jennifer, et al.
Publicado: (2017)

Blocking autophagy overcomes resistance to dual histone deacetylase and proteasome inhibition in gynecologic cancer
por: Bi, Jianling, et al.
Publicado: (2022)

Testing for NRAS Mutations in Serous Borderline Ovarian Tumors and Low-Grade Serous Ovarian Carcinomas
por: Sadlecki, Pawel, et al.
Publicado: (2018)

Development of Low-Grade Serous Ovarian Carcinoma from Benign Ovarian Serous Cystadenoma Cells
por: Dey, Puja, et al.
Publicado: (2022)

Fallopian tube origin of supposed ovarian high‐grade serous carcinomas
por: Diniz, Patricia Martini, et al.
Publicado: (2011)

Chemokine Ligand 5 to Predict Optimal Cytoreduction in Ovarian Cancer
por: Hidayat, Yudi Mulyana, et al.
Publicado: (2020)

Genomic Analysis Using Regularized Regression in High-Grade Serous Ovarian Cancer
por: Natanzon, Yanina, et al.
Publicado: (2018)

Paraneoplastic opsoclonus-myoclonus syndrome as a presentation of high grade serous ovarian cancer
por: Stewart, Kimberly T., et al.
Publicado: (2019)

Targeting the Microenvironment in High Grade Serous Ovarian Cancer
por: Nwani, Nkechiyere G., et al.
Publicado: (2018)

The Tumor Microenvironment of High Grade Serous Ovarian Cancer
por: Stack, M. Sharon, et al.
Publicado: (2018)

Cell Origins of High-Grade Serous Ovarian Cancer
por: Kim, Jaeyeon, et al.
Publicado: (2018)

Proteome profiling of low grade serous ovarian cancer
por: zadeh fakhar, Haniyeh Bashi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_b1uv9nn4u7k2s97jm76sk4on70